Trials / Conditions / Stage IIIA Skin Melanoma

Stage IIIA Skin Melanoma

17 registered clinical trials studyying Stage IIIA Skin Melanoma.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Thera NCT03719131	Emory University	Phase 2
Completed	Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partn NCT03112668	Rutgers, The State University of New Jersey	N/A
Completed	Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malig NCT03229278	Rutgers, The State University of New Jersey	Phase 1
Completed	Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer NCT03154190	Stanford University	N/A
Terminated	Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02748564	Rutgers, The State University of New Jersey	Phase 2
Completed	Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma NCT03028948	Rutgers, The State University of New Jersey	N/A
Withdrawn	Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplifica NCT02812693	Joanne Jeter	Phase 1 / Phase 2
Completed	Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel NCT02857374	Roswell Park Cancer Institute	N/A
Completed	MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Bee NCT02320305	Mayo Clinic	EARLY_Phase 1
Completed	Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma NCT01961115	Fred Hutchinson Cancer Center	Phase 2
Completed	Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Remove NCT01886235	Roswell Park Cancer Institute	N/A
Completed	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors NCT01522820	Roswell Park Cancer Institute	Phase 1
Completed	Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors NCT01131234	National Cancer Institute (NCI)	Phase 1
Completed	Recombinant Interferon Alfa-2b in Treating Patients With Melanoma NCT01460875	William Carson	N/A
Completed	Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV NCT00110019	National Cancer Institute (NCI)	Phase 3
Completed	Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has NCT01989559	National Cancer Institute (NCI)	Phase 1
Completed	Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma NCT00019682	National Cancer Institute (NCI)	Phase 3